Updated guidance on preventing atherosclerotic cardiovascular disease in people with dyslipidemia includes changes reflecting ...

Q4 2024 Earnings Call Transcript February 13, 2025 Alnylam Pharmaceuticals, Inc. misses on earnings expectations. Reported ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

NVS has put up a good Q4 performance on the back of momentum in its key drugs and should maintain it in 2025. Investors ...

Earnings reflect R&D investments in 2024 including the acquisition of Kate Therapeutics, Mariana Oncology, IFM Due, MorphoSys AG, Calypso Biotech BV, and SanReno Therapeutics. Additionally, as the ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

Q4 2024 Earnings Call Transcript January 31, 2025 Novartis AG beats earnings expectations. Reported EPS is $1.98, expectations were $1.8. Operator: Good morning and good afternoon, and welcome to the ...

Leqvio Sales Growth: 114% in constant currency for the full ... Proposed Dividend: CHF 3.50 per share, a 6% increase. Novartis AG (NYSE:NVS) reported a strong financial performance for 2024, with a 16 ...

Leqvio sales skyrocketed 83% to $223 million ... driven mainly by emerging growth markets. Novartis has a collaboration agreement with Roche RHHBY for Xolair. Novartis and Roche co-promote Xolair ...

Leqvio showed a steady trajectory ... And free cash flow grew 24% to $16.3 billion, a record high for Novartis. Now speaking of free cash flow, let's turn to the next slide.